U.S. Markets closed

Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher

Zacks Equity Research

Aratana Therapeutics, Inc. PETX was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $4.02 – $6.55 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Aratana Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Aratana Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.

Aratana Therapeutics, Inc. Price

Aratana Therapeutics, Inc. Price | Aratana Therapeutics, Inc. Quote

Another stock worth considering in the Medical – Drugs industry is Bellicum Pharmaceuticals, Inc. BLCM which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is PETX going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

 


 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aratana Therapeutics, Inc. (PETX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research